Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2017

View Archived Issues

Replimune doses first cohort in phase I/II study of RP-1

AstraZeneca presents regulatory and pipeline developments of third quarter 2017

Numerate receives grant from NIH to develop EZH2 inhibitor-coated orthopedic implants

Phase I PK data support continued development of COTI-2

Inozyme Pharma announces series A financing to develop its lead enzyme replacement therapy

Phase II results for Rottapharm's CR-4056 in knee osteoarthritis pain

Galapagos's GLPG-1972 well tolerated in healthy volunteers

Marketing applications for volanesorsen accepted in U.S., E.U. and Canada

Committee recommends continuation of phase III Atlantis study of Zepsyre

Zymeworks and Janssen Biotech enter license agreement to develop bispecific antibody therapeutics

PF-22688 reduces chronic pain induced by cancer in mouse and rat models

Lilly initiates phase II study of LY-3154207 in Parkinson's disease dementia

AstraZeneca begins phase I study of AZD-4573 in relapsed or refractory hematological malignancies

European Commission approves Trelegy Ellipta

First patient enrolled in Japanese TREASURE study of MultiStem in stroke

Nitric oxide-releasing chitosan BIOC-51 bactericidal against several pathogens

TiGenix announces European trade name and INN for Cx-601

FDA approves Mepsevii for mucopolysaccharidosis type VII

Samumed patents novel Wnt signaling inhibitors

Roche, Genentech describe new Janus kinase inhibitors

Novel vasopressin V1A and V2 receptor antagonists developed at Bayer

Inception 1 discovers novel NADPH oxidase 4 inhibitors

Rudong SIMR Biotech presents new GABRA5 inverse agonists

Sangamo treats first patient with in vivo genome editing therapy SB-913 for MPS II

Gout candidate URC-102 shows promise in phase II trials

Acorda updates status of phase III program of tozadenant following cases of agranulocytosis

GlaxoSmithKline studies GSK-2618960 in primary Sjogren's syndrome

AbbVie initiates phase I study of ABBV-321 in advanced solid tumors likely to overexpress EGFR

Atridia studies HTI-1090 for advanced solid tumors in phase I